Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
暂无分享,去创建一个
A. Sweet-Cordero | T. Jacks | J. Settleman | M. Giovannini | J. Sebolt-Leopold | J. Glickman | K. Shannon | K. Haigis | M. Haigis | M. Niwa-Kawakita | K. Kendall | Yufang Wang | A. Cheung
[1] T. Jacks,et al. Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex , 2007, Oncogene.
[2] A. Iafrate,et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling , 2007, Proceedings of the National Academy of Sciences.
[3] J. Gordon,et al. Inducible Gene Knockouts in the Small Intestinal and Colonic Epithelium* , 1999, The Journal of Biological Chemistry.
[4] R. Kucherlapati,et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.
[5] Channing J Der,et al. Increasing complexity of Ras signaling , 1998, Oncogene.
[6] Manuel Serrano,et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.
[7] R. DePinho,et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.
[8] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[9] Daniel Metzger,et al. Tissue‐specific and inducible Cre‐mediated recombination in the gut epithelium , 2004, Genesis.
[10] R. Ren,et al. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. , 2007, Cancer research.
[11] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[12] F. Cominelli,et al. Mouse models for the study of Crohn's disease. , 2003, Trends in molecular medicine.
[13] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[14] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[15] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Julie A. Wilkins,et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo , 2006, Proceedings of the National Academy of Sciences.
[17] Hideyuki Okano,et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. , 2003, Differentiation; research in biological diversity.
[18] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[19] M. Malumbres,et al. Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development , 2001, Molecular and Cellular Biology.
[20] Carmine Vecchione,et al. Replacement of K‐Ras with H‐Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice , 2005, EMBO reports.
[21] Thierry Soussi,et al. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. , 2002, Gastroenterology.
[22] R. Klemke,et al. Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.
[23] J. Pessin,et al. Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase , 1996, Molecular and cellular biology.
[24] M. Giovannini,et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers , 2004, Laboratory Investigation.
[25] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[26] Leroy Hood,et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis , 2007, Nature Genetics.
[27] S. Shirasawa,et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.
[28] J. Pouysségur,et al. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2003, Biochemical pharmacology.
[29] T. Jacks,et al. The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium* , 2006, Journal of Biological Chemistry.
[30] S. Söldner-Rembold,et al. The first 30 years , 1983 .
[31] C. Der,et al. Cellular N-Ras Promotes Cell Survival by Downregulation of Jun N-Terminal Protein Kinase and p38 , 2002, Molecular and Cellular Biology.
[32] R. Coffey,et al. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium , 2007, Journal of cellular physiology.
[33] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.
[34] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[35] Christopher S Potten,et al. The intestinal epithelial stem cell. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[36] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[37] G. Tzivion,et al. Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.
[38] P. Sharp,et al. Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Gordon,et al. Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.